Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients

Autor: Myrsini Ioakeim-Ioannidou, Andrzej Niemierko, Daniel W Kim, Athena Tejada, Tobias Urell, Shannon Leahy, Judy Adams, Barbara Fullerton, G Petur Nielsen, Yin P Hung, Angela R Shih, Manuel Patino, Karen Buch, Sandra Rincon, Hilary Kelly, Mary Beth Cunnane, Maria Tolia, Brigitte C Widemann, Mary F Wedekind, Liny John, David Ebb, John H Shin, Gregory Cote, William Curry, Shannon M MacDonald
Rok vydání: 2023
Předmět:
Zdroj: Neuro-Oncology.
ISSN: 1523-5866
1522-8517
DOI: 10.1093/neuonc/noad068
Popis: Background Data on clinical outcomes for base of skull (BOS) chordomas in the pediatric population is limited. We report patient outcomes after surgery and proton radiotherapy (PRT). Methods Pediatric patients with BOS chordomas were treated with PRT or combined proton/photon approach (proton-based; for most, 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Endpoints of interest were overall survival (OS), disease-specific survival, progression-free survival (PFS), freedom from local recurrence (LC), and freedom from distant failure (DC). Results Of 204 patients, median age at diagnosis was 11.1 years (range, 1–21). Chordoma location included 59% upper and/or middle clivus, 36% lower clivus, 4% craniocervical junction, and 1% nasal cavity. Fifteen (7%) received pre-RT chemotherapy. Forty-seven (23%) received PRT, and 157 (77%) received comboRT. Median total dose was 76.7 Gy (RBE) (range, 59.3–83.3). At a median follow-up of 10 years (interquartile range, 5–16 years), 56 recurred. Median OS and PFS were 26 and 25 years, with 5-, 10-, and 20-year OS and PFS rates of 84% and 74%, 78% and 69%, and 64% and 64%, respectively. Multivariable actuarial analyses showed poorly differentiated subtype, radiographical progression prior to RT, larger treatment volume, and lower clivus location to be prognostic factors for worse OS, PFS, and LC. RT was well tolerated at a median follow-up of 9 years (interquartile range, 4–16 years). Side effects included 166 patients (80%) with mild/moderate acute toxicities, 24 (12%) patients with late toxicities, and 4 (2%) who developed secondary radiation-related malignancies. Conclusion This is the largest cohort of BOS chordomas in the literature, pediatric and/or adult. High-dose PRT following surgical resection is effective with low rates of late toxicity.
Databáze: OpenAIRE
Externí odkaz: